CONTEXT: Report of a study published in the Annals of Hematology detailing the use of RWE to conduct a head-to-head comparison of treatments used in relapsed/refractory multiple myeloma. Retrospective analysis of electronic health records for patients taking bortezomib, carfilzomib, ixazomib, and daratumumab in combination with either lenalidomide or pomalidomide plus dexamethasone. Results showed important efficacy gaps between results from Phase 3 RCTs and those from the real-world analysis | US only data
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 7
1. “Patients were included if they initiated triplet regimens in their second line of therapy or later and were followed from 2007 through 2018.”
2. “A study published in the Annals of Hematology used real-world evidence to conduct head-to-head comparisons of triplet regimens for treatment of relapsed/refractory multiple myeloma (RRMM).”
3. “Lack of head-to-head trials of triplet regimens highlights the need for real-world evidence,” wrote the authors.”
4. “More patients in their second line of therapy received regimens including bortezomib than other triplets.”
5. “Average time to next treatment (TTNT) for each lenalidomide-based regimen was: 13.9 months for VRd; 8.7 months for KRd; 11.4 months for IRd; and not estimable (NE) for DRd.”